Paper Presentations: Medication-Related Issues — Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia (210-2)

5:05 – 5:25 pm Thursday, August 17
1CH  Asparaginase poses a substantial risk for hypersensitivity reactions; however, reactions vary by asparaginase type and administration route. Intravenous (IV) PEG-asparaginase has a higher hypersensitivity risk when compared to intramuscular administration. It is imperative that nurses be knowledgeable of clinical symptoms associated with IV PEG-asparaginase reactions, as well as the typical timing of these reactions.

This study described the clinical factors among patients receiving IV PEG-asparaginase hypersensitivity reactions, including reaction frequency and severity, dose number, phase of treatment, and time between infusion initiation and reaction onset.